✦ LIBER ✦

A phase I study of anti-GD3 ganglioside monoclonal antibody R24 and recombinant human macrophage-colony stimulating factor in patients with metastatic melanoma

✍ Scribed by Lori M. Minasian; Tzy Jyun Yao; Thomas A. Steffens; David A. Scheinberg; Linda Williams; Elyn Riedel; Alan N. Houghton; Paul B. Chapman

Publisher: John Wiley and Sons
Year: 1995
Tongue: English
Weight: 647 KB
Volume: 75
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19950501)75:9<2251::aid-cncr2820750910>3.0.co;2-f

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Analysis of therapeutic and immunologic

Analysis of therapeutic and immunologic effects of R24 anti-GD3 monoclonal antibody in 37 patients with metastatic melanoma

✍ John M. Kirkwood; Ruth A. Mascari; Howard D. Edington; Michael S. Rabkin; Roger 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 272 KB

## BACKGROUND. Antitumor effects of antibodies against ganglioside antigens of melanoma have been reported, but neither optimal doses nor mechanisms have been established. ## METHODS. This Phase IB trial of the murine immunoglobulin IgG 3 monoclonal antibody R 24 against disialoganglioside GD3

A phase I clinical and pharmacologic stu

A phase I clinical and pharmacologic study of a carboplatin and irinotecan regimen combined with recombinant human granulocyte-colony stimulating factor in the treatment of patients with advanced nonsmall cell lung carcinoma

✍ Hiroaki Okamoto; Akira Nagatomo; Hideo Kunitoh; Hiroshi Kunikane; Koshiro Watana 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 84 KB 👁 3 views

BACKGROUND. This Phase I study was designed to determine the toxicity and efficacy of a carboplatin and irinotecan (CPT-11) regimen with recombinant human granulocyte colony-stimulating factor (rhG-CSF) support for patients with advanced nonsmall cell lung carcinoma. ## METHODS. Treatment consist

Phase I, double-blind, randomized, place

Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease

✍ C. Janneke van der Woude; Pieter Stokkers; Ad A. van Bodegraven; Gert Van Assche 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 274 KB 👁 2 views

Background: NI-0401 is a fully human monoclonal antibody, which binds to the CD3 subunit of the T-cell receptor, causing modulation of T-cell activity. We investigated the safety and the ability to modulate the TCR-CD3 complex of NI-0401 in patients with active Crohn's disease (CD). Methods: A doub

Golimumab, a human anti–tumor necrosis f

Golimumab, a human anti–tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four–week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis

✍ Paul Emery; Roy M. Fleischmann; Larry W. Moreland; Elizabeth C. Hsia; Ingrid Str 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 135 KB 👁 1 views

Erratum: Golimumab, a human anti-tumor n

Erratum: Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis

✍ Paul Emery; Roy M. Fleischmann; Larry W. Moreland; Elizabeth C. Hsia; Ingrid Str 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 38 KB 👁 1 views